Pharmacological Characterization of FR194921, a New Potent, Selective, and Orally Active Antagonist for Central Adenosine A1 Receptors

Authors: Maemoto, Takuya ¹, Tada, Miho ¹, Mihara, Takuma ¹, Ueyama, Noriko ¹, Matsuoka, Hideaki ¹, Harada, Katsuya ¹, Yamaji, Takayuki ¹, Shirakawa, Kiyoharu ¹, Kuroda, Satoru ², Akahane, Atsushi ², Iwashita, Akinori ¹, Matsuoka, Nobuya ^{1, *}, Mutoh, Seitaro ¹

Source: In Journal of Pharmacological Sciences 2004 96(1):42-52

Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils

Authors: Katsuta, Kiyotaka, Umemura, Kazuo, Ueyama, Noriko, Matsuoka, Nobuya ^*

Source: In European Journal of Pharmacology 2003 467(1):103-109

Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy

Authors: Furuichi, Yasuhisa ^∗, Katsuta, Kiyotaka, Maeda, Masashi, Ueyama, Noriko, Moriguchi, Akira, Matsuoka, Nobuya, Goto, Toshio, Yanagihara, Takehiko

Source: In Brain Research 2003 965(1):137-145

A Combined Treatment With Tacrolimus (FK506) and Recombinant Tissue Plasminogen Activator for Thrombotic Focal Cerebral Ischemia in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.

Authors: Maeda, Masashi, Furuichi, Yasuhisa, Ueyama, Noriko, Moriguchi, Akira, Satoh, Natsuki, Matsuoka, Nobuya, Goto, Toshio, Yanagihara, Takehiko

Source: Journal of Cerebral Blood Flow & Metabolism; Oct2002, Vol. 22 Issue 10, p1205-1211, 7p